Joseph Wender - Ionis Pharmaceuticals Independent Director
| IONS Stock | USD 43.09 0.08 0.19% |
Director
Mr. Joseph H. Wender is an Independent Director of the Company. Mr. Wender began with Goldman, Sachs Co. in 1971 and became a General Partner of that firm in 1982, where he headed the Financial Institutions Group for over a decade. Since January 2008, he was a Senior Consultant to Goldman Sachs Co. He is a former Independent Trustee of the Schwab Family of Funds and is a Director of Grandpoint Capital, a bank holding company. Mr. Wender also is coCEO and partner of Colgin Cellars. Since March 2014, Mr. Wender was a director, and is currently Lead Director, of Outfront Media, lessors of advertising space on outofhome advertising structures. since 1994.
| Age | 73 |
| Tenure | 30 years |
| Address | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 |
| Phone | 760 931 9200 |
| Web | https://www.ionispharma.com |
Joseph Wender Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Wender against Ionis Pharmaceuticals stock is an integral part of due diligence when investing in Ionis Pharmaceuticals. Joseph Wender insider activity provides valuable insight into whether Ionis Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Ionis Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ionis Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Wender over six months ago Acquisition by Joseph Wender of 10321 shares of Ionis Pharmaceuticals subject to Rule 16b-3 |
Ionis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7634) %, meaning that it created substantial loss on money invested by shareholders. Ionis Pharmaceuticals' management efficiency ratios could be used to measure how well Ionis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.13 in 2024. Return On Capital Employed is likely to drop to -0.15 in 2024. At this time, Ionis Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 365.6 M in 2024, whereas Intangible Assets are likely to drop slightly above 24.2 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Amit Munshi | Pulmatrix | 50 | |
| Adrian Montgomery | Acasti Pharma | N/A | |
| Gregory French | Pulmatrix | 53 | |
| Kurt Graves | Pulmatrix | 47 | |
| Reed Tuckson | Acasti Pharma | 63 | |
| Terrance McGuire | Pulmatrix | 61 | |
| Valier Boivin | Acasti Pharma | N/A | |
| Tony Goodman | Adial Pharmaceuticals | 60 | |
| Robertson Gilliland | Adial Pharmaceuticals | 37 | |
| Akihisa Akao | Pulmatrix | 59 | |
| Richard Schottenfeld | Acasti Pharma | N/A | |
| JeanClaude Debard | Acasti Pharma | N/A | |
| David MacNaughtan | Jaguar Animal Health | 50 | |
| Richard Conley | Pulmatrix | 63 | |
| Pierre Fitzgibbon | Acasti Pharma | 60 | |
| John Micek | Jaguar Animal Health | 64 | |
| Jiahao Qiu | Jaguar Animal Health | 31 | |
| Donald Olds | Acasti Pharma | 57 | |
| Scott Rocklage | Pulmatrix | 60 | |
| Jonathan Siegel | Jaguar Animal Health | 44 | |
| Katherine Crewe | Acasti Pharma | N/A | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0751 |
Ionis Pharmaceuticals Leadership Team
Elected by the shareholders, the Ionis Pharmaceuticals' board of directors comprises two types of representatives: Ionis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ionis. The board's role is to monitor Ionis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ionis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ionis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Esq, Chief VP | ||
| Joseph Klein, Independent Director | ||
| Brett Monia, Sr. VP of Drug Discovery and Corporate Devel. | ||
| MA MBA, Executive CFO | ||
| Hayley Soffer, Vice Communications | ||
| Richard Geary, Executive Officer | ||
| Michael Hayden, Director | ||
| Spencer Berthelsen, Independent Director | ||
| Frederick Muto, Independent Director | ||
| Breaux Castleman, Independent Director | ||
| Onaiza CadoretManier, Chief VP | ||
| Peter Reikes, Director | ||
| Patrick ONeil, Senior Vice President - Legal, General Counsel | ||
| Ben Strain, IR Contact Officer | ||
| Lynne Parshall, COO, Corporate Secretary, Director | ||
| Joan Herman, Director | ||
| Dr BSc, Executive Officer | ||
| Joseph Loscalzo, Director | ||
| Eric Swayze, Ex Research | ||
| Joseph Wender, Independent Director | ||
| Wade Walke, Vice President - Corporate Communications | ||
| Sarah Boyce, Chief Business Officer | ||
| Frank Bennett, Senior Vice President - Antisense Research | ||
| JD Esq, Strategic Director | ||
| Damien McDevitt, Chief Business Officer | ||
| Joel Edwards, VP Operations | ||
| Stanley Crooke, Chairman of the Board and Presidentident, CEO | ||
| Elizabeth Hougen, CFO and Sr. VP of Fin. | ||
| Darren Gonzales, Chief VP |
Ionis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ionis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0751 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 5.9 B | ||||
| Shares Outstanding | 145.85 M | ||||
| Shares Owned By Insiders | 0.86 % | ||||
| Shares Owned By Institutions | 99.14 % | ||||
| Number Of Shares Shorted | 9.53 M | ||||
| Price To Earning | 101.16 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Ionis Stock analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Earnings Share (2.56) | Revenue Per Share 5.501 | Quarterly Revenue Growth 1.136 | Return On Assets (0.08) |
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.